A biotech based on the frightening fact that some cancer cells spread throughout the body even before a tumor is detectable emerged from stealth mode on Thursday, announcing it had raised roughly $60 million from, among others, early-stage venture capital companies and one of biotech’s 800-pound gorillas.
New York-based HiberCell plans to develop therapies targeted at the unique genetic signatures of “dormant disseminated tumor cells,” which years of research by scientific founder Julio Aguirre-Ghiso suggests are responsible for many, and perhaps most, cases of cancer relapse and metastasis.
About the Author Reprints
I’m interested in immunotherapy and prostate cancer.